Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company developing reformulations of existing generic drugs for new therapeutic uses. Its lead programs, LP-10 and LP-310, target hemorrhagic/radiation cystitis and oral lichen planus, while LP-50 is a preclinical bladder-cancer program built on the company’s proprietary epithelial-tissue drug delivery platform.
Tilikausi 2024 · muutos edellisvuodesta
Kehitys 2021–2024
Liiketoiminta
Osuus liikevaihdostaLP-10 and LP-310 are the company’s main development assets targeting unmet-need indications.
LP-50 is an earlier-stage intravesical bladder-cancer program using the same delivery approach.
The company’s formulation and delivery platform is designed for epithelial tissues such as bladder, mouth, and colon.
NIH grant revenue supports ongoing research and development activities.
Asiakkaat
Lipella does not yet sell approved products; its current economic “customers” are primarily grant providers and, in the future, patients, physicians, and hospitals that would use its therapies if approved. The company’s programs are aimed at severe conditions with limited or no approved treatment options, so adoption would depend on specialist prescribing and clinical evidence. In the near term, external funding sources such as NIH grants are important because they help finance development before commercialization.
Government and research grant providers fund development work before product sales exist.
Urologists, oncologists, and oral medicine specialists would prescribe the therapies if approved.
Clinical sites and hospital systems would administer or stock the products in specialty care settings.
Patients with hemorrhagic cystitis, oral lichen planus, or bladder cancer are the eventual end users.
Strategia
Lipella’s strategy is to reformulate known active ingredients into proprietary therapies for diseases with high unmet need, aiming to reduce development risk versus wholly novel molecules. The company is prioritizing advancement of LP-10 and LP-310 through clinical development while building optionality with LP-50 and protecting the platform with patents. Near-term execution depends on funding, trial progress, and regulatory milestones rather than commercial scale.
LP-10 and LP-310 are the main value drivers and need clinical proof to reach approval.
Patent coverage is central to monetizing reformulated drugs and defending against competitors.
The company is pre-revenue and must finance trials, manufacturing, and regulatory work.
Maantiede
Lipella is headquartered in the United States and its development, patent protection, and clinical activity are centered there. The company also has issued patents in Australia, Canada, and Europe, which broadens its potential commercial protection if products are approved. Because it is pre-commercial, geography currently matters more for regulatory approval, IP coverage, and clinical trial execution than for sales concentration.
Riskit
Lipella faces the classic risks of a clinical-stage biotech: trial failure, regulatory setbacks, and ongoing financing needs before any product revenue exists. Company-specific risks also include Nasdaq listing compliance issues, dilution from preferred stock conversions, and dependence on third-party CROs and manufacturers. Because the business is still pre-commercial, setbacks in funding or development could materially delay or prevent value creation.
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has ongoing losses and will likely need additional capital, which can dilute shareholders.
Kohdistuu: Capital structure
- Nasdaq continued listing riskVaikutus: KorkeaTodennäköisyys: Korkea
The company disclosed noncompliance with certain Nasdaq requirements, which could lead to delisting.
Kohdistuu: Trading liquidity and valuation
- Clinical development failureVaikutus: Korkea
LP-10, LP-310, and LP-50 have not yet been approved, so efficacy or safety issues could stop the programs.
Kohdistuu: Lead pipeline value
- Regulatory approval riskVaikutus: Korkea
Even positive data may not translate into FDA or other approvals, delaying commercialization.
Kohdistuu: All product candidates
- Third-party supply and CRO dependenceVaikutus: Keskitaso
Clinical and manufacturing work is outsourced, so vendor delays or failures can slow development.
Kohdistuu: Trial execution
Kirjanpito
Harkinnanvaraiset erätNIH grant revenue is recognized over time based on incurred costs and payment rights, affecting quarterly comparability.
Vaikutus: Revenue and operating loss timing
Clinical and CRO contracts may create termination fees and unrecoverable outlays that must be estimated.
Vaikutus: Liabilities and R&D expense
Persistent losses and funding needs make liquidity assumptions central to financial statement presentation.
Vaikutus: Disclosure and investor risk assessment
Preferred stock conversions can cause immediate dilution and affect share count and equity balances.
Vaikutus: Capital structure and per-share metrics
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
LB Pharmaceuticals Inc
LBRX · Pharmaceutical Preparations
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Lantern Pharma Inc.
LTRN · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Lyell Immunopharma, Inc.
LYEL · Pharmaceutical Preparations
Lyell Immunopharma is a U.S.-based late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer.
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Päivitetty: 24.9.2026